Moreover, genetic susceptibility testing with apolipoprotein E (apo E) is a form of genetic testing that is considered by some to apply to all of us. Those who carry the apo E allele are more at risk for the disease than those with apo E 2 or 3. However, the risk information in the case of susceptibility

testing is not as clear-cut as in the autosomal dominant setting. Thus, ethical inhibitor Ponatinib issues emerge as to how valuable information that is less precise is Inhibitors,research,lifescience,medical to individuals who consider themselves at risk. Risks of psychological harm and even suicide exist if bad news is given and especially if it is misinterpreted. Inhibitors,research,lifescience,medical Moreover, ethical issues follow genetic testing of both the susceptibility and autosomal dominant type as to who should

have sellckchem access to the information. For example, should insurance companies who might, modify the costs or availability of health insurance based on the results of genetic tests on individuals be informed? When a person crosses over the indistinct Inhibitors,research,lifescience,medical line from severe normal aging to mild AD, it is appropriate to consider “applying” the diagnosis to that individual. Diagnostic disclosure raises a number of ethical issues. Considerable cultural variation exists as to whether physicians and the public believe it, is ethical to inform individuals of their diagnosis and prognosis. In the United States and Northern Europe, it, is usually considered best, to allow the autonomous individual access to that Inhibitors,research,lifescience,medical information, whereas in oriental and southern European cultures, the family is often told and the patient is protected from the diagnosis. One major issue not, often considered in these discussions of the ethics of disclosure is what words are Inhibitors,research,lifescience,medical used when a diagnosis is given and how the information is actually processed by the individual and family. Their understanding

of what is said by the physician is often different from what he or she intended the message to be.13 Individuals should be encouraged to develop advance directives early in the disease. A living will is a document describing the kinds of care that the individual would like later in the illness when they may not be able to make their own health Drug_discovery care decisions. We are beginning to explore the use of such devices concerning decisions about research participation. In addition to a written document, the individual with dementia should identity the person, usually the caregiver, who will make decisions when the patient is not able to do so, ie, a surrogate decision-maker. How a caregiver should make the decisions is also an ethical issue.